Related Experiment Videos
Platelet-activating factor inhibits ciliary beat frequency of human bronchial epithelial cells
1Division of Pediatric Pneumology and Immunology, Charité, Humboldt University, Berlin, Germany.
Insights
Platelet-activating factor (PAF) reduces human bronchial ciliary beat frequency, impairing mucociliary clearance. A PAF inhibitor reversed this effect, indicating PAF
Area of Science:
- Respiratory Medicine
- Immunology
- Cell Biology
Background:
- Mucociliary clearance is vital for airway defense.
- Airway inflammation involves various mediators.
- Platelet-activating factor (PAF) is implicated in inflammatory processes.
Purpose of the Study:
- To investigate the impact of platelet-activating factor (PAF) on human bronchial ciliary beat frequency (CBF) ex vivo.
- To determine if PAF affects mucociliary clearance.
- To assess the role of PAF in airway inflammation.
Main Methods:
- Human bronchial brush biopsies were obtained from pediatric patients.
- Ciliary beat frequency (CBF) was measured using phase-contrast microscopy and a photoelectric technique.
- Ex vivo application of PAF (10(-5) M) and its inhibitor WEB 2086 (10(-4) M) to assess their effects on CBF.
Main Results:
- Platelet-activating factor (PAF) significantly reduced mean CBF by 2.1 Hz to 9.2 Hz (p < 0.05).
- The PAF-induced decrease in CBF was completely reversed by the PAF-inhibitor WEB 2086.
- WEB 2086 alone did not significantly alter CBF, confirming its specificity.
Conclusions:
- Platelet-activating factor (PAF) directly inhibits human bronchial ciliary beat frequency.
- PAF contributes to the impairment of mucociliary clearance.
- Targeting PAF may be a therapeutic strategy for airway inflammatory conditions.
Abstract:
The aim of our study was to investigate the effect of platelet-activating factor on human bronchial ciliary beat frequency (CBF) ex vivo. Brush biopsies were obtained from eight children (mean age 6.6 years) who underwent bronchoscopy for clinical reasons (i.e., foreign body aspiration, chronic cough, stridor). Immediate measurement of CBF by phase-contrast microscopy and photoelectric technique was performed before further treatment, and then on three subsamples: after adding platelet-activating factor (PAF) (10(-5) M); after adding the inhibitor WEB 2086 (10(-4) M); and after adding both PAF and WEB 2086. Addition of 10(-5) M PAF reduced mean CBF by 2.1 Hz to 9.2 Hz (p < 0.05). The inhibitory effect of PAF was completely reversed by the addition of the PAF-inhibitor WEB 2086, whereas WEB 2086 alone did not significantly influence CBF. Optimum PAF concentration had been determined in previous dose-response experiments. Our data indicates that PAF involved in airway inflammation contributes to a decrease in mucociliary clearance in humans.